000			01530 a2200469 4500
005			20250515075933.0
264		0	_c20070919
008			200709s 0 0 fre d
022			_a1660-9379
040			_aNLM _beng _cNLM
100	1		_aLamy, Olivier
245	0	0	_a[The necessity of cost-effectiveness analysis in osteoporosis]. _h[electronic resource]
260			_bRevue medicale suisse _cJun 2007
300			_a1521-5 p. _bdigital
500			_aPublication Type: English Abstract; Journal Article
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aBone Density Conservation Agents _xeconomics
650	0	4	_aCalcium _xeconomics
650	0	4	_aCost-Benefit Analysis
650	0	4	_aDecision Making
650	0	4	_aDiphosphonates _xeconomics
650	0	4	_aFemale
650	0	4	_aFractures, Bone _xeconomics
650	0	4	_aHealth Care Costs
650	0	4	_aHip Fractures _xeconomics
650	0	4	_aHormone Replacement Therapy _xeconomics
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMarkov Chains
650	0	4	_aMiddle Aged
650	0	4	_aModels, Economic
650	0	4	_aOrganometallic Compounds _xeconomics
650	0	4	_aOsteoporosis _xdrug therapy
650	0	4	_aParathyroid Hormone _xanalogs & derivatives
650	0	4	_aQuality of Life
650	0	4	_aSelective Estrogen Receptor Modulators _xeconomics
650	0	4	_aThiophenes _xeconomics
650	0	4	_aVitamin D _xeconomics
700	1		_aKrieg, Marc-Antoine
773	0		_tRevue medicale suisse _gvol. 3 _gno. 115 _gp. 1521-5
999			_c17214910 _d17214910